{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:09:49Z","timestamp":1773965389867,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Myxomatous mitral valve disease (MMVD) stands out as the most prevalent acquired canine heart disease. Its occurrence can reach up to 40% in small breed dogs and escalates in geriatric canine populations. MMVD leads to thickening and incomplete coaptation of valve leaflets during systole, resulting in secondary mitral valve regurgitation. Serious complications may arise concurrently with the worsening of mitral valve regurgitation, including left-and right-sided congestive heart failure, and pulmonary hypertension (PH). Ultimately, the PH progression might contribute to the patient\u2019s demise or to the owner\u2019s decision of euthanasia. Most currently available FDA-approved therapies for PH are costly and aim to address the imbalance between vasoconstriction and vasodilation to restore endothelial cell function. However, none of these medications impact the molecular dysfunction of cells or impede the advancement of pulmonary vascular and right ventricular remodeling. Recent evidence has showcased successful gene therapy approaches in laboratory animal models of PH. In this manuscript, we summarize the latest advancements in gene therapy for the treatment of PH in animals. The manuscript incorporates original data showcasing sample presentations, along with non-invasive hemodynamic assessments. Our findings demonstrate that the use of metabolic gene therapy, combining synthetic adeno-associated virus with acid ceramidase, has the potential to significantly reduce the need for drug treatment and improve spontaneously occurring PH in dogs.<\/jats:p>","DOI":"10.3389\/fvets.2024.1415030","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T11:19:21Z","timestamp":1727090361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Michael G.","family":"Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan G.","family":"Ohad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Putter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataly","family":"Shtraizent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehud","family":"Shahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smadar","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efrat","family":"Eliyahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"Keene","year":"2019","journal-title":"J Vet Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jvc.2012.01.011","article-title":"Historical review, epidemiology and natural history of degenerative mitral valve disease","volume":"14","author":"Borgarelli","year":"2012","journal-title":"J Vet Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jvc.2012.01.001","article-title":"Pulmonary hypertension in canine degenerative mitral valve disease","volume":"14","author":"Kellihan","year":"2012","journal-title":"J Vet Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/jvim.12564","article-title":"Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease","volume":"29","author":"Borgarelli","year":"2015","journal-title":"J Vet Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jvim.15725","article-title":"ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs","volume":"34","author":"Reinero","year":"2020","journal-title":"J Vet Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2460\/javma.229.11.1772","article-title":"Doppler-echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001\u20132005)","volume":"229","author":"Serres","year":"2006","journal-title":"J Am Vet Med Assoc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1760-2734(06)70055-8","article-title":"Comparison of primary mitral valve disease in German shepherd dogs and in small breeds","volume":"6","author":"Borgarelli","year":"2004","journal-title":"J Vet Cardiol"},{"key":"ref8","first-page":"440","article-title":"Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992\u20131996","volume":"13","author":"Johnson","year":"1999","journal-title":"J Vet Intern Med"},{"key":"ref9","first-page":"99","article-title":"Pulmonary hypertension and cardiovascular sequelae in 54 dogs","volume":"2","author":"Pyle","year":"2004","journal-title":"Inter J of Appl Res in Vet Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/j.1939-1676.2007.tb01947.x","article-title":"Sildenafil citrate therapy in 22 dogs with pulmonary hypertension","volume":"21","author":"Kellum","year":"2007","journal-title":"J Vet Inter Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1892\/07-064.1","article-title":"Diagnostic value of echo-Doppler and tissue Doppler imaging in dogs with pulmonary arterial hypertension","volume":"216","author":"Serres","year":"2007","journal-title":"J Vet Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1517\/14712598.2011.542139","article-title":"Gene therapy for pulmonary hypertension: prospects and challenges","volume":"11","author":"Reynolds","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3390\/ijms22031179","article-title":"Genetic delivery and gene therapy in pulmonary hypertension","volume":"22","author":"Rai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ejcts.2009.06.045","article-title":"Gene therapies for pulmonary hypertension-from experimental trials to bedside aspects","volume":"37","author":"Meng","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1161\/01.CIR.0000079161.56080.22","article-title":"Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells","volume":"108","author":"Nagaya","year":"2003","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ejcts.2004.08.031","article-title":"Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats","volume":"26","author":"Ono","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"L574","DOI":"10.1152\/ajplung.00327.2013","article-title":"Transgelin as a therapeutic target to prevent hypoxic pulmonary hypertension","volume":"306","author":"Zhang","year":"2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3892\/ijmm.2016.2773","article-title":"Suppression of the expression of hypoxia-inducible factor-1\u03b1 by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats","volume":"38","author":"Li","year":"2016","journal-title":"Int J Mol Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1159\/000430130","article-title":"Interruption of CD40 pathway improves efficacy of transplanted endothelial progenitor cells in monocrotaline induced pulmonary arterial hypertension","volume":"36","author":"YanYun","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1159\/000495331","article-title":"Galectin-3-mediated transdifferentiation of pulmonary artery endothelial cells contributes to hypoxic pulmonary vascular remodeling","volume":"51","author":"Zhang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1038\/s41598-020-64298-5","article-title":"Endothelial Twist1-PDGFB signaling mediates hypoxia-induced proliferation and migration of \u03b1SMA-positive cells","volume":"10","author":"Mammoto","year":"2020","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1165\/ajrcmb.23.6.4106","article-title":"Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats","volume":"23","author":"Partovian","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1161\/01.CIR.102.23.2880","article-title":"Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats","volume":"102","author":"Budts","year":"2000","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/01.CIR.101.8.923","article-title":"In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse","volume":"101","author":"Champion","year":"2000","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1161\/01.CIR.0000062688.76508.B3","article-title":"In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats","volume":"107","author":"Pozeg","year":"2003","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1165\/rcmb.2002-0120OC","article-title":"Lung overexpression of angiostatin aggravates pulmonary hypertension in chronically hypoxic mice","volume":"29","author":"Pascaud","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"L1182","DOI":"10.1152\/ajplung.00020.2006","article-title":"Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension","volume":"292","author":"Reynolds","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/mt.2012.70","article-title":"Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension","volume":"20","author":"Morecroft","year":"2012","journal-title":"Mol Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/nm.3695","article-title":"Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension","volume":"20","author":"Savai","year":"2014","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI23203","article-title":"Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension","volume":"115","author":"McMurtry","year":"2005","journal-title":"J Clin Invest"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/104303401300042401","article-title":"Adenovirus-mediated atrial natriuretic protein expression in the lung protects rats from hypoxia-induced pulmonary hypertension","volume":"12","author":"Louzier","year":"2001","journal-title":"Hum Gene Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1089\/104303403765701150","article-title":"Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats","volume":"14","author":"Vieillard-Baron","year":"2003","journal-title":"Hum Gene Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jtcvs.2004.09.013","article-title":"Gene transfer of a TIE2 receptor antagonist prevents pulmonary hypertension in rodents","volume":"129","author":"Kido","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCRESAHA.107.153023","article-title":"Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats","volume":"101","author":"Ito","year":"2007","journal-title":"Circ Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1161\/HYPERTENSIONAHA.107.091348","article-title":"Adeno-associated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats","volume":"50","author":"Ito","year":"2007","journal-title":"Hypertension"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.113.001585","article-title":"Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension","volume":"128","author":"Hadri","year":"2013","journal-title":"Circulation"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-023-02487-2","article-title":"Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction","volume":"24","author":"Katz","year":"2023","journal-title":"Respir Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"L406","DOI":"10.1152\/ajplung.00223.2017","article-title":"Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency","volume":"314","author":"Yu","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.celrep.2015.07.019","article-title":"In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector","volume":"12","author":"Zinn","year":"2015","journal-title":"Cell Rep"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00439-019-02025-5","article-title":"Special issue on canine genetics: animal models for human disease and gene therapies, new discoveries for canine inherited diseases, and standards and guidelines for clinical genetic testing for domestic dogs","volume":"138","author":"Shaffer","year":"2019","journal-title":"Hum Genet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ymthe.2017.05.004","article-title":"Optimization of retinal gene therapy for X-linked retinitis pigmentosa due to RPGR mutations","volume":"25","author":"Beltran","year":"2017","journal-title":"Mol Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.repbio.2013.12.007","article-title":"Dog as a model in studies on human hereditary diseases and their gene therapy","volume":"14","author":"Switonski","year":"2014","journal-title":"Reprod Biol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/humc.2015.004","article-title":"Gene therapy studies in a canine model of X-linked severe combined immunodeficiency","volume":"26","author":"Felsburg","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/jth.13301","article-title":"Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies","volume":"14","author":"Nichols","year":"2016","journal-title":"J Thromb Haemost"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"11253","DOI":"10.1074\/jbc.M709166200","article-title":"Autoproteolytic cleavage and activation of human acid ceramidase","volume":"283","author":"Shtraizent","year":"2008","journal-title":"J Biol Chem"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/j.jtcvs.2021.05.050","article-title":"Efficient cardiac gene transfer and early-onset expression of a synthetic adeno-associated viral vector, Anc80L65, after intramyocardial administration","volume":"164","author":"Katz","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/jamp.2009.0806","article-title":"Influence of particle size and material properties on mucociliary clearance from the airways","volume":"23","author":"Henning","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jcdd6010008","article-title":"Targeted gene delivery through the respiratory system: rationale for intratracheal gene transfer","volume":"6","author":"Katz","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e31927","DOI":"10.7759\/cureus.31927","article-title":"Ethical perspectives of therapeutic human genome editing from multiple and diverse viewpoints: a scoping review","volume":"14","author":"Joseph","year":"2022","journal-title":"Cureus"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1415030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T11:19:23Z","timestamp":1727090363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1415030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":50,"alternative-id":["10.3389\/fvets.2024.1415030"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2024.1415030","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"article-number":"1415030"}}